Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07741526 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)

Study acronym: AD Biomarker
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
The study aims to measure safety, tolerability and biomarker-based efficacy of NPI-001 (AT-001) in Subjects with MCI or Alzheimer's Disease (AD). In the study participants receive increasing dose of active treatment (250mg vs 500mg vs 750mg) or matched placebo in the form of tablets BID.
Trial Details
NCT Number NCT07741526
Lead Sponsor Arctic Therapeutics
Collaborators: Blueskin AS
Conditions
(from sponsor)		 Alzheimer´s Disease
Related terms Cognitive Dysfunction, Dementia
Enrollment 33 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov